#JPM20: After Year of NASH collapses, all eyes on two biotechs
SAN FRANCISCO – It’s not quite Dewey defeats Truman, but Goldman Sachs calling 2019
Related Articles
Novo and Viatris settle Ozempic patent suit as generic entry date remains unknown
Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster diabetes drug Ozempic. The Danish company declined to…
Special report 2024: Meet 20 women breaking new ground in biopharma R&D
Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter at Endpoints from 2018-2020.…
RSV vaccines off to a sluggish start in US this season, with volumes behind 2023
This season’s uptake of RSV vaccines in the US has been slower than expected, according to Wall Street analysts tracking prescriptions, and appears to be…
BARDA doles out $72M to Sanofi, GSK and CSL for bird flu vaccine supply
The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to help fortify the US supply of bird…
J&J discontinues mid-stage dengue study, citing deprioritization of communicable disease work
What’s left of Johnson & Johnson’s infectious disease work continues to shrink, after the company announced Friday that it had stopped work on a mid-stage…
RSV vaccines off to a sluggish start in US this season, with volumes behind 2023
This season’s uptake of RSV vaccines in the US has been slower than expected, according to Wall Street analysts tracking prescriptions, and appears to be…
GSK’s ViiV stops development of Phase 2 HIV antiviral
GSK’s ViiV Healthcare has suspended development of a Phase 2-stage HIV antiviral named VH3739937, a GSK spokesperson confirmed to Endpoints News on Tuesday. The halt…
AI and Pathology: Now and the Future
Dr. Sanjay Patel of Weill Cornell and Dr. Greg Goldgof of Memorial Sloan Kettering dive into the transformative role of AI in modern pathology. They…
FDA pledges to take next steps on advisory committee changes
As the potential end of Robert Califf’s time as FDA commissioner nears, he and a key deputy are continuing to push forward with changes to…
Survivorship and the International Myeloma Foundation With Yelak Biru
Yelak Biru, President and CEO of the International Myeloma Foundation (IMF), joins the show to share his remarkable personal and professional journey. After imm